Особенности гемореологии и гемостаза при ВЗК у детей, коррекция изменений

Воспалительные заболевания кишечника (ВЗК) являются серьезной проблемой в детской гастроэнтерологии и требуют более глубокого и детального изучения. Патогенез ВЗК основан на генетической предрасположенности, реализация которой происходит под воздействием агрессивных факторов внешней среды и состояния кишечной микрофлоры, что приводит к каскаду воспалительных реакций в стенке кишечника. Однако до настоящего время механизм развития ВЗК остается не до конца изученным, в связи с чем проведение литературного обзора по вопросам особенностей гемореологии и гемостаза у детей с этой патологией является актуальным для последующего изучения этого вопроса c целью оптимизации терапии. Материалы и методы исследования. Поиск источников литературы проводился с использованием библиотечных платформ: PubMed, eLIBRARY. Все источники не более пяти лет давности.

воспалительные заболевания кишечника, язвенный колит, болезнь Крона, дети, гемореология, гемостаз, гипербарическая оксигенация

1. Fabián O., Kamaradová K. Morphology of inflammatory bowel diseases (IBD). Cesk Patol. 2022 Spring; 58(1):27-37. English. PMID: 35387455.

2. Kelsen J.R., Russo P., Sullivan K.E. Early-Onset Inflammatory Bowel Disease. Immunol Allergy Clin North Am. 2019 Feb; 39(1):63-79. doi: 10.1016/j.iac.2018.08.008.

3. Fuller M.K. Pediatric Inflammatory Bowel Disease: Special Considerations. Surg Clin North Am. 2019 Dec; 99(6):1177-1183. doi: 10.1016/j.suc.2019.08.008.

4. Spencer E.A., Dubinsky M.C. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am. 2021 Dec; 68(6):1171-1190. doi: 10.1016/j.pcl.2021.07.011.

5. Na S.Y., Kim Y.S. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs. Korean J Intern Med. 2022 Sep; 37(5):906-919. doi: 10.3904/kjim.2022.152.

6. Chatelain D., Moslemi A., Dreau A., Clement M. Les maladies inflammatoires chroniques intestinales (MICI) et tube digestif haut [Inflammatory bowel diseases and upper gastrointestinal tract]. Ann Pathol. 2023 Jun; 43(3):192-201. French. doi: 10.1016/j.annpat.2022.12.002.

7. Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019 Dec 1; 2019:7247238. doi: 10.1155/2019/7247238.

8. Peric S., Todorovic Z., Zdravkovic N. et al. Treatment of Ulcerative Colitis: Impact on Platelet Aggregation. Medicina (Kaunas). 2023 Sep 7; 59(9):1615. doi: 10.3390/medicina59091615.

9. Meianu C., Andrei S., Diculescu M., Longrois D., Guinot P.G., Droc G. Rotational Thromboelastometry Coagulation Parameters (ROTEM®) May be Discriminative for Active Inflammatory Bowel Disease: A Prospective Observational Study. J Gastrointestin Liver Dis. 2023 Sep 28; 32(3):298-305. doi: 10.15403/jgld-4810. PMID: 37774216.

10. Melazzini F., Calabretta F., Lenti M.V., Di Sabatino A. Venous thromboembolism in chronic gastrointestinal disorders. Expert Rev Gastroenterol Hepatol. 2022 May; 16(5):437-448. doi: 10.1080/17474124.2022.2072295.

11. Szakács Z., Csiszár B., Kenyeres P. et al. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol. BMJ Open. 2019 Mar 23; 9(3): e026315. doi: 10.1136/bmjopen-2018-026315.

12. Iourinets J., Sawalski C., Desai P. et al. Prevalence and outcome of acute pulmonary embolism in hospitalized patients with a history of inflammatory bowel disease. Thromb Res. 2024 Jul; 239:109035. doi: 10.1016/j.thromres.2024.05.008.

13. Keller K., Sivanathan V., Schmitt V.H., Ostad M.A., Münzel T., Espinola-Klein C., Hobohm L. Incidence and impact of venous thromboembolism in hospitalized patients with Crohn’s disease. Thromb Res. 2022 Nov; 219:77-85. doi: 10.1016/j.thromres.2022.09.009.

14. Borjas-Howard J.F., Leeuw K., Rutgers A., Meijer K., Tichelaar V.Y.I.G. Risk of Recurrent Venous Thromboembolism in Autoimmune Diseases: A Systematic Review of the Literature. Semin Thromb Hemost. 2019 Mar;45(2):141-149. doi: 10.1055/s-0038-1661387.

15. Lugonja S.I., Pantic I.L., Milovanovic T.M. et al. Atherosclerotic Cardiovascular Disease in Inflammatory Bowel Disease: The Role of Chronic Inflammation and Platelet Aggregation. Medicina (Kaunas). 2023 Mar 11; 59(3):554. doi: 1.0.3390/medicina59030554.

16. Petrey A.C., de la Motte C.A. Hyaluronan in inflammatory bowel disease: Cross-linking inflammation and coagulation. Matrix Biol. 2019 May; 78-79:314-323. doi: 10.1016/j.matbio.2018.03.011.

17. Hu W., Li P., Zeng N., Tan S. Exploring the hub mechanisms of ischemic stroke based on protein-protein interaction networks related to ischemic stroke and inflammatory bowel disease. Sci Rep. 2023 Jan 31; 13(1):1741. doi: 10.1038/s41598-023-27459-w.

18. Wu H., Xu M. [Platelet activation in inflammatory bowel disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Aug 28; 44(8):931-934. Chinese. doi: 10.11817/j.issn.167-7347.2019.180192.

19. Niu Y., Li A., Xu W. et al. Platelet activation stimulates macrophages to enhance ulcerative colitis through PF4/CXCR3 signaling.Int J Mol Med. 2025 May;55(5):78. doi: 10.3892/ijmm.2025.5519.

20. Anka Idrissi D., Senhaji N., Aouiss A. et al. IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn’s disease and new therapeutic targets. Arch Pharm Res. 2021 Jan; 44(1):117-132. doi: 10.1007/s12272-020-01296-1.

21. Detrez I., Thomas D., Van Steen K. et al. Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients. J Clin Gastroenterol. 2020 Oct; 54(9):819-825. doi: 10.1097/MCG.0000000000001290.

22. Sano Y., Tomiyama T., Yagi N. et al. Platelet activation through CD62P and the formation of platelet-monocyte complexes are associated with the exacerbation of mucosal inflammation in patients with ulcerative colitis. Sci Rep. 2024 Nov 14;14(1):28055. doi: 10.1038/s41598-024-78462-8.

23. Boccatonda A., Balletta M., Vicari S., Hoxha A., Simioni P., Campello E. The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review. Semin Thromb Hemost. 2023 Oct; 49(7):744-755. doi: 10.1055/s-0042-1758869.

24. Lagrange J., Lacolley P., Wahl D., Peyrin-Biroulet L., Regnault V. Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Jun; 19(6):1088-1097.e6. doi: 10.1016/j.cgh.2019.12.043.

25. Lagrange J., Ahmed M.U., Arnone D. et al. Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis. Inflamm Bowel Dis. 2024 Dec 5;30(12):2500-2508. doi: 10.1093/ibd/izae142.

26. Leibovitzh H., Lee S.H., Xue M. et al; CCC GEM Project Research Consortium; Turpin W., Croitoru K. Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn’s Disease. Gastroenterology. 2022 Nov; 163(5):1364-1376.e10. doi: 10.1053/j.gastro.2022.07.004.

27. Dull K, Fazekas F, Törőcsik D. Factor XIII-A in Diseases: Role Beyond Blood Coagulation.Int J Mol Sci. 2021 Feb 1; 22(3):1459. doi: 10.3390/ijms22031459.

28. Ollech J.E., Waizbard A., Lubetsky A., Kopylov U., Goren I., Dotan I., Yanai H. Venous Thromboembolism Among Patients With Inflammatory Bowel Diseases is Not Related to Increased Thrombophilia: A Case-Control Study. J Clin Gastroenterol. 2022 Mar 1; 56(3): e222-e226. doi: 10.1097/MCG.0000000000001578.

29. Schellenberg C., Lagrange J., Ahmed M.U. et al. The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease. J Crohns Colitis. 2024 May 31; 18(5):751-761. doi: 10.1093/ecco-jcc/jjad198.

30. Klavina P.A., Leon G., Curtis A.M., Preston R.J.S. Dysregulated haemostasis in thrombo-inflammatory disease. Clin Sci (Lond). 2022 Dec 22;136(24):1809-1829. doi: 10.1042/CS20220208.

31. Leppkes M., Lindemann A., Gößwein S. et al. Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis. Gut. 2022 Dec; 71(12):2414-2429. doi: 10.1136/gutjnl-2021-324725.

32. Leon G., Klavina P.A., Rehill A.M. et al. Tissue factor-dependent colitogenic CD4+ T cell thrombogenicity is regulated by activated protein C signalling. Nat Commun. 2025 Feb 16;16(1):1677. doi: 10.1038/s41467-025-57001-7.

33. Lagrange J., Lacolley P., Wahl D., Peyrin-Biroulet L., Regnault V. Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Jun; 19(6):1088-1097.e6. doi: 10.1016/j.cgh.2019.12.043.

34. Liu P., Li Y., Wang R., Ren F., Wang X. Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease. Bio.medicines. 2022;10:85. doi: 10.3390/ biomedicines10010085.

35. Alenazi N., Alsaeed H., Alsulami A., Alanzi T. A Review of Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease.Int J Gen Med. 2021 Oct 24; 14:7099-7105. doi: 10.2147/IJGM.S336678.